6.4 Cutaneous Malignancies & Blistering Disorders

Cutaneous Malignancies & Blistering Disorders

Prompt diagnosis of cutaneous neoplasms and blistering eruptions requires integrating clinical morphology, microscopic architecture, immunofluorescent patterns, and staging criteria. Recognizing high-risk malignancies and severe cutaneous adverse reactions prevents life-threatening complications.

Non-Melanoma Cutaneous Malignancies & Precursors

Basal Cell Carcinoma (BCC) is the most common cutaneous malignancy in humans (~80% of skin cancers):

• Clinical Presentation: Classically appears on sun-exposed head and neck areas as a pearly, translucent papule or nodule with prominent overlying telangiectasias, rolled borders, and central ulceration ("rodent ulcer").
• Histopathology: Demonstrates nests of basaloid keratinocytes extending from the epidermis into the dermis with characteristic peripheral palisading of nuclei and specialized stromal retraction artifact.
• Behavior & Management: BCC exhibits extremely low metastatic potential (< 0.1%), but is locally invasive and destructive. Diagnosis is established via punch or excisional biopsy. Definitive treatment involves surgical excision with 3 to 5 mm margins. Mohs micrographic surgery (intraoperative complete margin assessment) is indicated for lesions located in high-risk anatomic zones (facial regions, nose, eyelids, ears), recurrent tumors, or aggressive histologic subtypes.

Squamous Cell Carcinoma (SCC) is the second most common skin cancer (~20%):

• Clinical Presentation: Presents as an indurated, erythematous, scaly plaque or nodule, often with central ulceration or hyperkeratotic crusting on sun-exposed areas (lower lip, ears, dorsum of hands).
• Precursor Lesions: Actinic Keratosis (AK) represents a premalignant lesion caused by UV radiation damage, presenting as rough, red, "sandpaper-like" papules. Un-treated AKs progress to invasive SCC at a rate of 0.1% to 1% per year. AKs are treated with cryotherapy, topical 5-fluorouracil, or imiquimod. Marjolin ulcer refers to an aggressive form of SCC arising within chronic non-healing burn scars or sinus tracts.
• Histopathology: Demonstrates atypical keratinocytes invading the dermis with keratin pearls and intercellular bridges.
• Behavior & Management: SCC possesses moderate metastatic risk (2% to 5%, higher for lip and ear lesions). Surgical excision with 4 to 6 mm margins or Mohs surgery is curative.

Melanoma Pathophysiology & Biopsy Protocols

Cutaneous Melanoma is the most lethal skin malignancy, arising from transformed melanocytes:

• ABCDE Criteria: Asymmetry, Border irregularity, Color variation (variegated black, brown, red, blue), Diameter >= 6 mm, and Evolution/Enlargement over time.
• Subtypes: Superficial spreading (70% of cases, prominent radial growth phase), Nodular (early vertical growth phase, aggressive), Lentigo maligna (elderly sun-damaged facial skin), and Acral lentiginous (occurs on palms, soles, and subungual sites; most common subtype in dark-skinned individuals, unrelated to UV light exposure).
• Prognostic Determination: Breslow depth (measured in millimeters from the stratum granulosum to the deepest tumor cell) is the single most important prognostic factor for localized melanoma.
• Biopsy Protocol: Full-thickness excisional biopsy with 1 to 3 mm narrow margins is mandatory for suspicious pigmented lesions. Shave biopsies are strictly contraindicated because partial transection invalidates accurate Breslow depth measurement and tumor staging.
• Staging & Surgical Margins: Sentinel lymph node biopsy (SLNB) is indicated for melanomas with Breslow depth > 0.8 mm (or < 0.8 mm with ulceration or high mitotic rate). Wide local excision margin guidelines are based on Breslow depth: Melanoma in situ = 0.5 cm margin; thickness <= 1.0 mm = 1.0 cm margin; 1.01 to 2.0 mm = 1.0 to 2.0 cm margin; > 2.0 mm = 2.0 cm margin. Metastatic melanoma is tested for BRAF V600E mutations (treated with targeted BRAF/MEK inhibitors, e.g., dabrafenib + trametinib) and immune checkpoint inhibitors (anti-PD-1 pembrolizumab).

Autoimmune Blistering Disorders

Autoimmune blistering diseases are defined by target autoantigens and anatomical level of skin cleavage:

• Pemphigus Vulgaris (PV): Autoimmune disease caused by IgG autoantibodies targeting Desmoglein-3 (and Desmoglein-1), components of desmosomes mediating cell-to-cell adhesion in the epidermis.

  • Clinical Presentation: Flaccid, painful bullae that rupture easily, leaving extensive raw, denuded erosions. Positive Nikolsky sign (gentle lateral pressure on normal-appearing skin causes epidermal detachment). Mucous membrane involvement (painful oral ulcers) occurs first in > 80% of patients.
  • Histopathology & DIF: Shows acantholysis (loss of keratinocyte adhesion) producing intraepidermal bullae with a row of basal cells attached to the basement membrane ("tombstoning"). Direct Immunofluorescence (DIF) reveals a classic "net-like" or "chicken-wire" pattern of IgG and C3 throughout the epidermal intercellular space.
  • Management: High-dose systemic oral corticosteroids (prednisone 1 mg/kg/day) combined with rituximab (anti-CD20 monoclonal antibody).

• Bullous Pemphigoid (BP): Autoimmune disease in elderly patients (> 60 years) caused by IgG autoantibodies against hemidesmosomal antigens (BP180 and BP230) at the dermal-epidermal junction.

  • Clinical Presentation: Large, tense, firm bullae on normal or erythematous skin. Bullae resist rupture. Negative Nikolsky sign. Intensely pruritic urticarial prodrome. Mucous membranes are characteristically spared (or mildly involved in < 20%).
  • Histopathology & DIF: Shows subepidermal bullae filled with eosinophils. DIF demonstrates a continuous linear band of IgG and C3 along the basement membrane zone.
  • Management: High-potency topical corticosteroids (clobetasol propionate cream) for localized disease; oral corticosteroids plus azathioprine or mycophenolate for severe cases.

• Dermatitis Herpetiformis (DH): Autoimmune cutaneous manifestation of Celiac Disease driven by IgA autoantibodies against epidermal transglutaminase. Presents with intensely pruritic, grouped papules and small vesicles symmetrically distributed over extensor surfaces (elbows, knees, buttocks). DIF shows granular IgA deposits within dermal papillae. Treatment requires a strict gluten-free diet and oral dapsone (provides rapid symptomatic relief within 24-48 hours; mandatory G6PD deficiency screening prior to dapsone initiation to prevent severe hemolytic anemia).

Severe Cutaneous Adverse Reactions (SJS / TEN)

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent life-threatening drug-induced hypersensitivity reactions marked by widespread keratinocyte apoptosis and full-thickness epidermal necrosis. High-risk offending drugs include allopurinol, antiepileptics (carbamazepine, phenytoin, lamotrigine), sulfonamides (TMP-SMX), and NSAIDs.

• Clinical Presentation: Begins 1 to 3 weeks post-drug exposure with a prodrome of fever, malaise, and upper respiratory symptoms, followed by painful dusky erythematous macules, targetoid lesions, flaccid bullae, and a positive Nikolsky sign. Multi-mucosal involvement (oral, ocular, and urogenital erosions) occurs in > 90% of cases.
• BSA Classification: Categorized by percentage of total body surface area exhibiting epidermal detachment:
  • SJS: < 10% BSA detachment.
  • SJS/TEN Overlap: 10% to 30% BSA detachment.
  • TEN: > 30% BSA detachment.
• Management Protocol: Immediate discontinuation of the offending drug is the single most critical intervention. Patients mandate immediate transfer to an Intensive Care Unit (ICU) or Burn Center. Supportive care includes aggressive fluid replacement, sterile wound care, nutritional support, and mandatory urgent ophthalmology consultation to prevent cicatrizing conjunctivitis, corneal ulceration, and permanent blindness.

Diagnostic Algorithm: Pigmented Lesion Evaluation & Staging

[ Suspicious Pigmented Cutaneous Lesion ]
                   │
       ├─► Apply ABCDE Criteria (Asymmetry, Border, Color, Diameter >= 6mm, Evolution)
                   │
                   ▼
   [ Full-Thickness Excisional Biopsy ] (1-3 mm margins; NO SHAVE BIOPSY!)
                   │
                   ▼
      [ Histopathologic Evaluation ]
                   │
       ┌───────────┴───────────┐
       ▼                       ▼
[ Breslow Depth <= 0.8 mm ]   [ Breslow Depth > 0.8 mm ]
       │                       │
       ├─► Wide Local Excision ├─► Sentinel Lymph Node Biopsy (SLNB)
       │   (1 cm margin)       ├─► Wide Local Excision (1-2 cm margin)
       │                       └─► BRAF V600E Mutation Testing (if metastatic)
       ▼                       ▼
[ Routine Follow-up ]   [ Targeted / Immunotherapy ]

Comparative Matrix of Autoimmune & Drug-Induced Blistering Disorders